Sonida Senior Living (NYSE:SNDA – Get Free Report) and NeoGenomics (NASDAQ:NEO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Sonida Senior Living and NeoGenomics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sonida Senior Living | 1 | 2 | 5 | 0 | 2.50 |
| NeoGenomics | 1 | 2 | 7 | 1 | 2.73 |
Sonida Senior Living currently has a consensus price target of $47.50, suggesting a potential upside of 20.07%. NeoGenomics has a consensus price target of $16.71, suggesting a potential downside of 1.56%. Given Sonida Senior Living’s higher probable upside, equities analysts plainly believe Sonida Senior Living is more favorable than NeoGenomics.
Volatility & Risk
Insider and Institutional Ownership
87.5% of Sonida Senior Living shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 39.3% of Sonida Senior Living shares are owned by company insiders. Comparatively, 1.1% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Sonida Senior Living and NeoGenomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sonida Senior Living | -23.27% | -25.53% | -6.67% |
| NeoGenomics | -6.77% | -1.99% | -1.21% |
Valuation & Earnings
This table compares Sonida Senior Living and NeoGenomics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sonida Senior Living | $381.14 million | 4.99 | -$70.78 million | ($6.19) | -6.39 |
| NeoGenomics | $727.33 million | 3.00 | -$108.03 million | ($0.40) | -42.45 |
Sonida Senior Living has higher earnings, but lower revenue than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.
Summary
NeoGenomics beats Sonida Senior Living on 10 of the 15 factors compared between the two stocks.
About Sonida Senior Living
Sonida Senior Living, Inc. develops, owns, operates, and manages senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It also offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, the company provides memory care services; and home care services through third-party providers. As of December 31, 2021, it operated 75 senior housing communities in 18 states with an aggregate capacity of approximately 9,500 residents, including 60 senior housing communities. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Addison, Texas.
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Receive News & Ratings for Sonida Senior Living Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonida Senior Living and related companies with MarketBeat.com's FREE daily email newsletter.
